News and Media

“Tchaikapharma is the first Bulgarian organization to support the Stand Up To Cancer initiative. What was your motivation and why now?   SU2C is massively supported by the entertainment industry and leading global media with a very critical and self-critical view on the funding and implementation of scientific programs and research. With one important exception […]

The second scientific conference “Fundamentals of Cardiovascular Pharmacotherapy – Combination Therapy” was held in Sofia between May 12-14, 2023 on the initiative of the Academy-Cardiology Foundation, Logartis Foundation and Arbilis Ltd, in collaboration with the Bulgarian Society of Pharmacy and the National Association of General Practitioners in Bulgaria. As a leading manufacturer of combination products […]

“We have assured quantities of medicines manufactured at Tchaikapharma High Quality Medicines. Based on current consumption, we maintain a minimum of a 4-month supply. If there is increased demand, we are ready to respond.”

Tchaikapharma’s latest medicinal product to receive marketing authorisation from the Bulgarian Drug Agency is Clopasa (colchicine) 0.5 mg tablets – the first gout treatment in the company’s broad portfolio.   Clopasa belongs to the group of medicines with antipathic action. It is used for the treatment of acute attacks of gout, in the condition of […]

The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is: Semefro 50 mg/850 mg film-coated tablets Semefro 50 mg/1000 mg film-coated tablets   Active ingredients: sitagliptin/metformin hydrochloride   Semefro contains two different medicines called sitagliptin and metformin. – Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) […]